GVD-28112-88518
2 vaccinations
2 coded responses
24 check-ins
2 free-text entries
1 call case
- Sex
- Female
- Age at first dose
- 31-35
- ZIP prefix
- 483 / MI
- Registered
- 2020-12-31
- Relationship
- Self
- Race
- Multiracial
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2020-12-31
Registered in v-safe
-
2020-12-31
Dose 1 — Pfizer-BioNTech
- 2020-12-31
- 2021-01-01
- 2021-01-02
- 2021-01-03
- 2021-01-04
-
2021-01-06
Health check-in — days 1–6 daily, dose 1Feeling: Fair · Fever · Fatigue or tirednessAdult check-in
- 2021-01-07
- 2021-01-14
-
2021-01-21
Dose 2 — Pfizer-BioNTech
- 2021-01-21
-
2021-01-22
Survey response — days 1–6 daily, dose 2MedDRA: Night sweats — Feeling: Fair · Site: Pain · HeadacheFree text: Night sweatsMedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
- 2021-01-23
- 2021-01-24
- 2021-01-25
- 2021-01-26
- 2021-01-27
- 2021-01-28
- 2021-02-04
- 2021-02-11
- 2021-02-18
- 2021-02-25
- 2021-03-05
- 2021-04-24
- 2021-07-22
-
2022-01-21
Survey response — 12 months, dose 2MedDRA: Ageusia, Anosmia, Dyspnoea, Fatigue, Pyrexia, Urinary retention — Feeling: Fair · Be unable to work or attend school, Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · Telehealth, virtual health, or email health consultationFree text: Fatigue- shortness of breath - loss of taste and smell - low grade fever - urine retentionMedDRA releases: 2024-11 · check-in free text available
-
2022-01-21
Report sent to call center — 12 months, dose 2Be unable to work or attend school · Be unable to do your normal daily activities · Get care from a doctor or other healthcare prTelehealth, virtual health, or email health consultation · 1 call case(s)
-
2022-01-24
Call successfulNot applicable (accidental reporting or does not believe symptoms are related to vaccine)
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2020-12-31 | Pfizer-BioNTech | |
| 2 | 2021-01-21 | Pfizer-BioNTech |
Call center
1 call center case
1 successful
Free text
Release 2 — days 1–6 daily, dose 2
Systemic reaction (other): Night sweats
Release 11 — 12 months, dose 2
Symptoms: Fatigue- shortness of breath - loss of taste and smell - low grade fever - urine retention
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Ageusia | · | · | ✓ |
| SD | Anosmia | · | · | ✓ |
| SD | Dyspnoea | · | · | ✓ |
| SD | Fatigue | · | · | ✓ |
| SD | Pyrexia | · | · | ✓ |
| SD | Urinary retention | · | · | ✓ |
| SRO | Night sweats | ✓ | ✓ | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release